On this page
I-cell disease (mucolipidosis II)
This condition is characterised by the accumulation of specific complex molecules within cells, particularly in the lysosomes. It leads to progressive damage in various organs and typically presents in infancy.
Available at Jeen Health
Clinical tests that include this
Overview
I-cell disease, medically termed mucolipidosis II, is a rare genetic disorder that affects the body's ability to process and recycle waste within cells. It belongs to a group of conditions known as lysosomal storage disorders. Lysosomes are often described as the 'recycling centres' of the cell, responsible for breaking down various substances into smaller components that the cell can reuse or excrete [PMID:31761358].
In I-cell disease, a crucial enzyme responsible for 'tagging' other enzymes for delivery to the lysosomes is faulty. Without this tag, these enzymes cannot reach their proper destination and instead accumulate outside the lysosomes or are secreted from the cell. This leads to a build-up of undigested materials within the lysosomes, causing them to swell and impair cell function, particularly in connective tissues, bones, and organs such as the heart and liver.
The exact prevalence of I-cell disease is estimated to be between 1 in 100,000 and 1 in 400,000 live births, making it a very rare condition. Symptoms usually become apparent shortly after birth or within early infancy.
Symptoms & clinical features
The symptoms of I-cell disease are typically severe and progressive, often noticeable within the first few months of life. Affected infants may present with distinctive facial features, including a flat nasal bridge, full cheeks, and prominent gums, which can become more pronounced with age. Growth delays are common, leading to short stature.
Skeletal abnormalities are a hallmark of the condition, often involving bone deformities and joint stiffness that limit movement. This can include issues like clubfoot and hip dislocation. Other common features include an enlarged liver and spleen (hepatosplenomegaly), and heart valve thickening, which can lead to heart problems [PMID:31761358].
Many infants with I-cell disease experience recurrent respiratory infections due to weakened airways and may have feeding difficulties. Developmental delays are also frequently observed, affecting both motor skills and cognitive development.
Video: Genetics 101
Affected organs
I-cell disease affects multiple organ systems throughout the body due to the widespread nature of lysosomal dysfunction. The skeletal system is significantly impacted, leading to widespread bone deformities (dysostosis multiplex), joint contractures, and growth plates abnormalities. Connective tissues, including cartilage, are also severely affected, contributing to joint stiffness and bone issues.
The cardiovascular system is commonly involved, with thickening of heart valves, which can impair heart function. The liver and spleen often become enlarged, though their function may remain relatively preserved early on. The respiratory system can be compromised, leading to chronic respiratory issues and an increased susceptibility to infections. While the brain is affected, the primary neurological impact is often developmental delay rather than severe neurodegeneration typical of some other lysosomal storage disorders.
Risks & severity
I-cell disease is considered a severe condition with a progressive course. The severity of symptoms can vary somewhat between individuals, but it generally leads to significant health challenges from early infancy. Life expectancy is often reduced, with many children not surviving beyond early childhood due to complications such as heart failure and respiratory infections [PMID:31761358].
The condition is present from birth, though signs may not be fully apparent immediately. The progressive nature means that symptoms tend to worsen over time, with increasing skeletal deformities, joint stiffness, and organ involvement. Early diagnosis and supportive care are crucial for managing symptoms and improving quality of life, but there is currently no cure for the underlying disease.
Genetic causes
I-cell disease is caused by pathogenic variants in the *GNPTAB* gene. This gene provides instructions for making two parts (the alpha and beta subunits) of an enzyme called N-acetylglucosamine-1-phosphate transferase (GlcNAc-1-phosphotransferase) [PMID:32506456].
This enzyme plays a vital role in the proper functioning of lysosomes, the cell's recycling centres. Its job is to attach a specific chemical tag, mannose-6-phosphate, to certain enzymes destined for the lysosomes. This tag acts like an address label, ensuring these enzymes are correctly delivered to the lysosomes where they are needed to break down waste products.
When there are pathogenic variants in *GNPTAB*, the GlcNAc-1-phosphotransferase enzyme is either non-functional or has reduced activity. As a result, the lysosomal enzymes do not receive their mannose-6-phosphate tags, and cannot be transported effectively to the lysosomes. Instead, they are often secreted outside the cell or accumulate in other parts of the cell, leading to a build-up of undigested materials within the lysosomes and the characteristic features of I-cell disease.
- GNPTAB N-acetylglucosamine-1-phosphate transferase subunits alpha and betaThe GNPTAB gene provides instructions for producing subunits of an enzyme critical for transporting digestive enzymes to lysosomes, cellular compartments responsible for waste breakdown.
Inheritance pattern
I-cell disease is inherited in an autosomal recessive pattern. This means that a child must inherit two altered copies of the *GNPTAB* gene - one from each parent - to develop the condition.
If an individual inherits only one altered copy of the *GNPTAB* gene and one normal copy, they are typically a 'carrier' and do not show symptoms of I-cell disease. When two carriers have a child, there is a 25% (1 in 4) chance with each pregnancy that their child will inherit two altered copies and develop I-cell disease. There is a 50% (2 in 4) chance the child will be a carrier like the parents, and a 25% (1 in 4) chance the child will inherit two normal copies of the gene and not be affected or a carrier.
When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.
Diagnosis & testing
Diagnosis of I-cell disease is typically suspected based on characteristic clinical signs and symptoms observed in infancy. These include the distinctive facial features, skeletal abnormalities, developmental delays, and organ enlargement. Blood tests may show elevated levels of certain lysosomal enzymes in the blood plasma, which is a key indicator of the condition.
Confirmation of I-cell disease is made through genetic testing, which looks for pathogenic variants in the *GNPTAB* gene. Genetic testing for lysosomal storage disorders like I-cell disease is available through the NHS Genomic Medicine Service. A referral to a clinical genetics service is usually made by a paediatrician or other specialist when I-cell disease is suspected. The relevant R-code for genomic testing for lysosomal storage disorders can be identified via the National Genomic Test Directory.
Management & lifestyle
There is currently no specific cure for the underlying genetic cause of I-cell disease. Management focuses on supportive care to alleviate symptoms and improve the quality of life for affected individuals. This involves a multidisciplinary approach tailored to the specific needs of each patient.
Treatment strategies often include physiotherapy to help manage joint stiffness and maintain mobility. Orthopaedic interventions may be required to address skeletal deformities. Cardiac care is important to monitor and manage heart valve issues. Respiratory support, such as antibiotics for infections or airway clearance techniques, may also be needed.
Nutritional support is often crucial due to feeding difficulties. Regular monitoring by a team of specialists, including paediatricians, cardiologists, orthopaedists, physiotherapists, and geneticists, is essential. Genetic counselling is also recommended for affected families to understand the inheritance pattern and reproductive options.
UK care pathway
In the UK, individuals suspected of having genetic conditions like I-cell disease are typically referred to a clinical genetics service. This usually occurs following initial assessment by a general practitioner or a specialist, such as a paediatrician. Genetic counsellors within these services provide information, support, and guidance to individuals and families affected by genetic conditions.
Genomic testing for I-cell disease is available through the NHS Genomic Medicine Service (GMS) as part of the National Genomic Test Directory. The specific tests offered fall under various R-codes depending on the clinical presentation and suspected diagnosis, often as part of broader panels for lysosomal storage disorders. Samples are processed by NHS Genomic Laboratory Hubs.
Frequently asked questions
What is the difference between I-cell disease and mucolipidosis III?
Both I-cell disease (mucolipidosis II) and mucolipidosis III are caused by pathogenic variants in the *GNPTAB* gene. I-cell disease is generally more severe, with an earlier onset in infancy and more pronounced symptoms affecting multiple organ systems. Mucolipidosis III typically has a later onset, often in childhood, and a milder range of symptoms, though it can still be progressive.
Is there a cure for I-cell disease?
Currently, there is no cure for the underlying genetic cause of I-cell disease. Treatment focuses on managing the symptoms and complications of the condition through supportive care. This includes therapies such as physiotherapy, orthopaedic interventions, cardiac management, and nutritional support to improve quality of life.
How is I-cell disease diagnosed?
Diagnosis is usually suspected based on a baby's clinical features, such as distinctive facial characteristics, skeletal abnormalities, and developmental delays. Blood tests showing elevated levels of certain enzymes can provide further clues. The diagnosis is confirmed through genetic testing to identify pathogenic variants in the *GNPTAB* gene.
If I have one child with I-cell disease, what is the risk for future children?
Since I-cell disease is inherited in an autosomal recessive pattern, if you have one child with the condition, it means both parents are carriers. For each subsequent pregnancy, there is a 25% (1 in 4) chance that the child will inherit two altered gene copies and be affected by I-cell disease. Genetic counselling can provide detailed information and discuss reproductive options.
What kind of medical team will look after a child with I-cell disease?
A child with I-cell disease will typically be cared for by a multidisciplinary team. This often includes a paediatrician, a clinical geneticist, a metabolic specialist, a cardiologist, an orthopaedist, physiotherapists, and dietitians. This team works together to manage the various symptoms and provide comprehensive care.
References
- Yanda MK, Liu Q, Cebotaru L. A potential strategy for reducing cysts in autosomal dominant polycystic kidney disease with a CFTR corrector. The Journal of biological chemistry. 2018. PMID: 29875161